Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population

Laura Bartels-Peculis,1 Ajay Sharma,2 Alison M Edwards,2 Anirudh Sanyal,2 Erin Connolly-Strong,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Inc., Bedminster, NJ, USA; 2Healthagen LLC, New York, NY 10017, USACorrespondence: Laura Bartels-Peculis Email laura.bartels@mnk.comObjective: To describe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bartels-Peculis L, Sharma A, Edwards AM, Sanyal A, Connolly-Strong E, Nelson WW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	lupus nephritis provider visits health care resource utilization health care costs real-world evidence Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/8a65a16b78114d8ab20e88b0ccc6d608
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a65a16b78114d8ab20e88b0ccc6d608
record_format	dspace
spelling	oai:doaj.org-article:8a65a16b78114d8ab20e88b0ccc6d6082021-12-02T13:13:00ZTreatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population1179-156Xhttps://doaj.org/article/8a65a16b78114d8ab20e88b0ccc6d6082020-06-01T00:00:00Zhttps://www.dovepress.com/treatment-patterns-and-health-care-costs-of-lupus-nephritis-in-a-unite-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XLaura Bartels-Peculis,1 Ajay Sharma,2 Alison M Edwards,2 Anirudh Sanyal,2 Erin Connolly-Strong,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Inc., Bedminster, NJ, USA; 2Healthagen LLC, New York, NY 10017, USACorrespondence: Laura Bartels-Peculis Email laura.bartels@mnk.comObjective: To describe the characteristics, treatment patterns, health care resource utilization (HCRU), and cost of care for members of a large United States (US) health insurance plan with lupus nephritis (LN).Methods: A retrospective observational study was conducted using a health insurance plan database to identify adult members with a diagnosis of LN. Medical and pharmacy claims were used to describe demographics, comorbidities, HCRU, and cost patterns over a 12-month follow-up period for each patient, between January 1, 2014, and December 31, 2016. All study variables were examined descriptively.Results: A total of 1039 patients were available for analysis (median age, 47 years; 83% female). The median Charlson Comorbidity Index (CCI) was 3.3. Less than half (41%) of patients received immunosuppressive therapies commonly used to treat LN. Evidence indicated that 58% of the study population were prescribed corticosteroid therapy, in most cases (73%) for more than 60 days. Adverse events known to be associated with corticosteroid therapy were recorded in 58% of patients. Guideline-recommended preventive therapy with hydroxychloroquine was prescribed for 54% of members with LN. Nearly half (47%) of members with LN did not see a nephrologist and more than one-third (36%) did not see a rheumatologist over 1 year of follow-up. Rates of all-cause hospitalization and emergency department (ED) use were 25% and 35%, respectively. The mean all-cause per-member-per-month (PMPM) medical cost for the study population was $2801, with LN-specific costs accounting for $1147 PMPM.Conclusion: Patients with LN who are insured through a large US health plan appeared to underutilize outpatient specialist services and guideline-recommended hydroxychloroquine therapy. Corticosteroid use and adverse events known to be associated with corticosteroids were common in this cohort.Keywords: lupus nephritis, provider visits, health care resource utilization, health care costs, real-world evidenceBartels-Peculis LSharma AEdwards AMSanyal AConnolly-Strong ENelson WWDove Medical Pressarticlelupus nephritisprovider visitshealth care resource utilizationhealth care costsreal-world evidenceDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 12, Pp 117-124 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	lupus nephritis provider visits health care resource utilization health care costs real-world evidence Diseases of the musculoskeletal system RC925-935
spellingShingle	lupus nephritis provider visits health care resource utilization health care costs real-world evidence Diseases of the musculoskeletal system RC925-935 Bartels-Peculis L Sharma A Edwards AM Sanyal A Connolly-Strong E Nelson WW Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
description	Laura Bartels-Peculis,1 Ajay Sharma,2 Alison M Edwards,2 Anirudh Sanyal,2 Erin Connolly-Strong,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Inc., Bedminster, NJ, USA; 2Healthagen LLC, New York, NY 10017, USACorrespondence: Laura Bartels-Peculis Email laura.bartels@mnk.comObjective: To describe the characteristics, treatment patterns, health care resource utilization (HCRU), and cost of care for members of a large United States (US) health insurance plan with lupus nephritis (LN).Methods: A retrospective observational study was conducted using a health insurance plan database to identify adult members with a diagnosis of LN. Medical and pharmacy claims were used to describe demographics, comorbidities, HCRU, and cost patterns over a 12-month follow-up period for each patient, between January 1, 2014, and December 31, 2016. All study variables were examined descriptively.Results: A total of 1039 patients were available for analysis (median age, 47 years; 83% female). The median Charlson Comorbidity Index (CCI) was 3.3. Less than half (41%) of patients received immunosuppressive therapies commonly used to treat LN. Evidence indicated that 58% of the study population were prescribed corticosteroid therapy, in most cases (73%) for more than 60 days. Adverse events known to be associated with corticosteroid therapy were recorded in 58% of patients. Guideline-recommended preventive therapy with hydroxychloroquine was prescribed for 54% of members with LN. Nearly half (47%) of members with LN did not see a nephrologist and more than one-third (36%) did not see a rheumatologist over 1 year of follow-up. Rates of all-cause hospitalization and emergency department (ED) use were 25% and 35%, respectively. The mean all-cause per-member-per-month (PMPM) medical cost for the study population was $2801, with LN-specific costs accounting for $1147 PMPM.Conclusion: Patients with LN who are insured through a large US health plan appeared to underutilize outpatient specialist services and guideline-recommended hydroxychloroquine therapy. Corticosteroid use and adverse events known to be associated with corticosteroids were common in this cohort.Keywords: lupus nephritis, provider visits, health care resource utilization, health care costs, real-world evidence
format	article
author	Bartels-Peculis L Sharma A Edwards AM Sanyal A Connolly-Strong E Nelson WW
author_facet	Bartels-Peculis L Sharma A Edwards AM Sanyal A Connolly-Strong E Nelson WW
author_sort	Bartels-Peculis L
title	Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
title_short	Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
title_full	Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
title_fullStr	Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
title_full_unstemmed	Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
title_sort	treatment patterns and health care costs of lupus nephritis in a united states payer population
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8a65a16b78114d8ab20e88b0ccc6d608
work_keys_str_mv	AT bartelspeculisl treatmentpatternsandhealthcarecostsoflupusnephritisinaunitedstatespayerpopulation AT sharmaa treatmentpatternsandhealthcarecostsoflupusnephritisinaunitedstatespayerpopulation AT edwardsam treatmentpatternsandhealthcarecostsoflupusnephritisinaunitedstatespayerpopulation AT sanyala treatmentpatternsandhealthcarecostsoflupusnephritisinaunitedstatespayerpopulation AT connollystronge treatmentpatternsandhealthcarecostsoflupusnephritisinaunitedstatespayerpopulation AT nelsonww treatmentpatternsandhealthcarecostsoflupusnephritisinaunitedstatespayerpopulation
_version_	1718393396808122368

Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population

Ejemplares similares